Drug intelligence / Profile preview

venetoclax

Development stage: Approved
Lead developer: AbbVie
Modality: Small Molecules
Administration: Oral

Overview

Venetoclax is an oral, small molecule antineoplastic agent used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). It is a selective B-cell lymphoma 2 (BCL-2) inhibitor that works by binding to the BCL-2 protein, which is overexpressed in certain cancer cells. By inhibiting BCL-2, venetoclax restores the process of apoptosis (programmed cell death) in malignant cells, leading to their destruction. Venetoclax is indicated as monotherapy or in combination with other agents such as rituximab or obinutuzumab for CLL/SLL and with azacitidine, decitabine, or low-dose cytarabine for AML. The drug was developed by AbbVie and Genentech/Roche.

Brand names: VenclextaVenclyxto
Other names: venetoclax

Targets

BCL-2 (BCL-2 family)

Beyond the preview

Go deeper on venetoclax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on venetoclax.

Explore the full profile